PATENT CLAIM ANALYSIS

Application Number: 15766212
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "093210"]

Abstract:
Provided herein are methods and compositions useful for treating cancer, such as prostate cancer, through adoptive cell transfer of T cells derived from patients and genetically engineered to express MDA-7/IL-24 and/or other immune modulating agents. The methods described herein result in cancer cell death and reprogramming of the tumor immune compartment to restore antitumor immunity both at a primary tumor site and systemically.

Claim (Index 23):
The method of  claim 19 , wherein said T lymphocyte is genetically modified to further express at least one of MDA-7/IL-24, IL-12, and MDA-5.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 91.0
- Lexical Diversity: 1.26415
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14660484', '14254235', '13240009', '14650775', '13669194']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7460303131298939
- 35 USC 102 Novelty (BERT): 0.5243848023226201
- Combined Prediction Score: 0.7238657620491665
- Mean Citation Score: 302.133908
- Max Citation Score: 315.64066
- Similarity Product: 195.2085826024604

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test